McKesson
  • Careers
  • Investors
  • Contact Us
  • Customer Logins
Solutions 
  • Providers
    All Solutions for Providers

    Distribution

    • Pharmaceutical Ordering and Packaging
    • Medical Supplies and Equipment

    Technology and Services

    • Growth and Expansion
    • Operational Efficiency
    • Patient and Clinical Care
    • Regulatory and Risk Management
    • Reimbursement and Revenue Cycle Management
  • Pharmacies
    All Solutions for Pharmacies

    Distribution

    • Pharmaceutical Distribution
    • Supplies, Equipment and Merchandise

    Expertise and Technology

    • Financial Performance
    • Growth and Expansion
    • Medication Adherence and Clinical Performance
    • Operational Efficiency
  • Health Plans
    All Solutions for Health Plans

    High Volume Pharmacy Automation

    • Centralized Drug Dispensing Service
    • Centralized Drug Dispensing System
    • Central Fill Pharmacy Automation

    Solutions for Health Plans

    • Real-Time Pharmacy Benefit Plan Design
    • Medical Claims Processing
    • Patient Care Solutions
    • Oncology Management
  • Manufacturers
    All Solutions for Manufacturers
    • Pharmaceutical Distribution
    • Third Party Logistics
    • Pharmaceutical Packaging
    • Clinical Trial Services
    • Health Care Informatics
    • Commercial Services

All Solutions

Providers 
  • All Solutions for Providers

Distribution

  • Pharmaceutical Ordering and Packaging
  • Medical Supplies and Equipment

Technology and Services

  • Growth and Expansion
  • Operational Efficiency
  • Patient and Clinical Care
  • Regulatory and Risk Management
  • Reimbursement and Revenue Cycle Management
Pharmacies 
  • All Solutions for Pharmacies

Distribution

  • Pharmaceutical Distribution
  • Supplies, Equipment and Merchandise

Expertise and Technology

  • Financial Performance
  • Growth and Expansion
  • Medication Adherence and Clinical Performance
  • Operational Efficiency
Health Plans 
  • All Solutions for Health Plans

High Volume Pharmacy Automation

  • Centralized Drug Dispensing Service
  • Centralized Drug Dispensing System
  • Central Fill Pharmacy Automation

Solutions for Health Plans

  • Real-Time Pharmacy Benefit Plan Design
  • Medical Claims Processing
  • Patient Care Solutions
  • Oncology Management
Manufacturers 
  • All Solutions for Manufacturers
  • Pharmaceutical Distribution
  • Third Party Logistics
  • Pharmaceutical Packaging
  • Clinical Trial Services
  • Health Care Informatics
  • Commercial Services
All Solutions
Blog
About Us
More >
  • Home
  • About McKesson
  • Newsroom
  • Press Releases
  • McKesson Reports Fiscal 2006 Second Quarter Results
Share
  • RSS
  • Facebook
  • Twitter
  • Linkedin
  • Email
  • Print

McKesson Reports Fiscal 2006 Second Quarter Results

November 08, 2005

SAN FRANCISCO--(BUSINESS WIRE)--Nov. 8, 2005--McKesson Corporation (NYSE:MCK)

-- Revenues of $21.6 billion, up 8%.

-- Second quarter net income of $167 million, up 94%, and diluted EPS of 53 cents, up 83%.

-- Net income from continuing operations of $154 million, up 79%, and diluted EPS from continuing operations of 49 cents, up 69%.

-- Year-to-date cash flow from operations of $2 billion compared to $365 million for the first six months a year ago.

McKesson Corporation (NYSE:MCK) today reported that revenues for the company's second quarter ended September 30, 2005, were $21.6 billion, an increase of 8% over the prior year. Second quarter net income was $167 million or 53 cents per fully diluted share, compared to $86 million or 29 cents per fully diluted share in the second quarter a year ago. Second quarter net income includes an after-tax gain of $13 million or four cents per share for the sale of the McKesson BioServices business unit, which is reported as a discontinued operation. Second quarter net income from continuing operations was $154 million or 49 cents per fully diluted share.

"Our significant improvement in operating profit and earnings per share from a year ago was due to an outstanding performance in Pharmaceutical Solutions," said John H. Hammergren, chairman and chief executive officer. "Pharmaceutical Solutions operating profit increased 69%, reflecting our continued focus on expanding our operating margin, the progress we have made evolving our relationships with pharmaceutical manufacturers and continued growth in our generics programs. We also had another excellent quarter in Provider Technologies."

"Our evolving relationships with manufacturers combined with more efficient inventory management in our U.S. pharmaceutical distribution business continue to be the primary factors producing record operating cash flow. In addition, at the end of our second quarter, we benefited from some favorable timing in our working capital accounts. Year-to-date, operating cash flow was $2 billion, compared to $365 million for the first six months a year ago."

"This record cash flow has enabled us to continue to apply a portfolio approach to shareholder value creation - a mix of strategic acquisitions, share repurchases and dividends. Year-to-date, we have spent $575 million on acquisitions, including D&K Healthcare Resources (D&K) and Medcon, $290 million to repurchase shares and $36 million to pay dividends."

"McKesson was fortunate to have experienced little impact to our operations or facilities from the devastation of Hurricanes Katrina and Rita. We were proud to have played a role in providing pharmaceuticals, medical supplies and nurse triage services to the affected areas. We are continuing to support the recovery of our affected customers and employees."

Segment Results

"For the quarter, Pharmaceutical Solutions revenues were up 8%, reflecting growth from our customers who are winning in the marketplace, new and expanded distribution agreements, revenue growth in our Canadian operations and revenues from D&K. This revenue increase was offset in part by slowing market growth and slower growth of customer warehouse sales than we achieved a year ago."

"Pharmaceutical Solutions operating margin expanded 44 basis points to 1.23%, reflecting our progress with manufacturers and an increased mix of generics. Margin expansion was partially offset by increases in operating expenses, including those of D&K. We are now moving aggressively to integrate the D&K operations and deliver operating efficiencies as we retain the customer base. While execution work remains, we are making great progress, and once we have completed our integration plan, this business should be accretive to segment results next fiscal year."

"Medical-Surgical Solutions revenue was up 8%, with growth across all sectors of the business. Revenue growth among alternate site customers was strong as we began seasonal shipments of flu vaccine. Operating profit was $23 million compared to $18 million in the second quarter a year ago, which included a litigation settlement charge."

"In Provider Technologies, revenues were up 18%, with software and software systems revenues up 32%. We continue to see strong demand for our clinical and imaging software solutions and automation systems, and are focused on accelerating the pace of our implementations. Bookings were also strong in the quarter, including several large agreements that include software, pharmacy automation, supply chain automation, cabinets and bedside scanning technology in unique solutions designed to reduce medication errors and improve efficiencies."

"Operating profit was up 37%, from $19 million to $26 million. We have begun integrating the Medcon cardiology solution into our overall clinical and imaging offering. This acquisition had a $3 million negative impact on segment operating profit in the quarter and will continue to be negative throughout this fiscal year, but it should be accretive to Fiscal 2007 results. With the increasingly positive trends toward more I.T. purchases by hospitals, we have also increased investments in development and sales to expand our market position over the next several years."

Outlook

"Turning to the balance sheet, we ended the quarter with almost $3 billion in cash. Using our strong balance sheet and significant operating cash flow, combined with our improving financial performance, we plan to continue our portfolio approach to create shareholder value."

"During the quarter, we repurchased $224 million of shares, completing the previous $250 million authorization and beginning a new $250 million share repurchase program approved in August. Over time, we have a goal of repurchasing shares to offset the dilution resulting from the exercise of stock options."

"We are clearly pleased with the momentum we have across McKesson. Based on our positive year-to-date results and the continued progress in our business, for the fiscal year ending March 31, 2006, McKesson expects to earn $2.25 to $2.40 per fully diluted share from continuing operations, excluding any adjustments to the securities litigation reserve," Hammergren concluded.

The guidance range is based on a tax rate for continuing operations for Fiscal 2006 of approximately 35%, up from original guidance of 32.5%. Partially offsetting the impact of the increased tax rate is a $37 million pre-tax gain from an anti-trust settlement which will be recorded in this year's third quarter. The EPS range also assumes approximately 315 million shares in the dilution calculation.

As previously announced, by order entered September 28, 2005, the Honorable Ronald M. Whyte granted preliminary approval of the proposed settlement of the consolidated class action pending in the U.S. District Court for the Northern District of California and established a schedule for further proceedings, including a hearing date of January 27, 2006 on final approval of the settlement. McKesson now expects to be able to fund the pending $960 million consolidated class action settlement from cash.

Corporate Highlights

The second quarter included the following news at the company:

In advance of Hurricane Katrina, McKesson established a back-up network of regional distribution centers to deliver pharmaceutical products to the Gulf Coast. Following the onset of the storm, these facilities remained open over Labor Day weekend for emergency deliveries. McKesson chartered a helicopter and a plane to make deliveries to areas isolated by flooding. In addition, McKesson employees and the McKesson Foundation have contributed more than $1 million to hurricane relief efforts, including $300,000 to the McKesson Employees Relief Fund to help displaced colleagues.

Following McKesson's acquisition of D&K Healthcare Resources, Inc., the company signed an amended supply agreement with D&K's largest customer group, American Pharmacy Cooperative, Inc., (APCI), a member-owned group purchasing organization representing more than 1,400 independent pharmacies. Over the past 12 months, APCI members purchased $1.3 billion of pharmaceuticals from D&K.

Revenues from generic sales were up 18% in the quarter, 22% year-to-date. McKesson's strong market position was a major factor in the decision by Teva Pharmaceuticals to select McKesson as the lead distributor for its recent launch of generic Allegra. The company's proven rapid generic distribution capabilities facilitated the product's successful delivery to customers.

McKesson's Valu-Rite(R) network of independently owned pharmacies was the highest rated pharmacy chain nationwide in a survey of 20,000 pharmacy customers conducted by Wilson Health Information, a leading consumer research firm. Valu-Rite(R) pharmacists earned the highest satisfaction ratings for personal service, convenience, and access to important health information and also scored very high on providing medication safety information, coordination of care, help with managed care, advice on non-prescription products and customer service.

McKesson signed an agreement with the Centers for Medicare & Medicaid Services (CMS) to offer a Medicare Health Support pilot program to pre-selected Medicare beneficiaries in Mississippi. McKesson will provide health education and support to approximately 20,000 pre-identified, fee-for-service Medicare beneficiaries with heart failure and/or diabetes. Beneficiaries will also have access to a free, 24X7 nurse advice line. Enrollments began in August.

McKesson Medical-Surgical strengthened its position in the long-term care sector of the market by re-signing its largest customer, HCR-Manor Care, to a new three-year agreement.

McKesson signed several large contracts to supply Horizon Clinical solutions and automation products to a range of customers, including Medical University of South Carolina, a large academic medical center with more than 600 physicians; Clinton Memorial Hospital, a 100-bed community hospital in Wilmington, Ohio; and Doctor's Medical Center, a major public hospital in San Pablo, California, near San Francisco.

Risk Factors

Except for historical information contained in this press release, matters discussed may constitute "forward-looking statements", within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These statements may be identified by their use of forward-looking terminology such as "believes", "expects", "anticipates", "may", "should", "seeks", "approximates", "intends", "plans", "estimates" or the negative of these words or other comparable terminology. The most significant of these risks and uncertainties are described in the company's Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission and include, but are not limited to: the resolution or outcome of pending shareholder litigation regarding the 1999 restatement of our historical financial statements; the changing U.S. healthcare environment, including the impact of potential future mandated benefits; changes in private and governmental reimbursement or in the delivery systems for healthcare products and services; governmental efforts to regulate the pharmaceutical supply chain; changes in pharmaceutical and medical-surgical manufacturers' pricing, selling, inventory, distribution or supply policies or practices; changes in customer mix; substantial defaults in payment or a material reduction in purchases by large customers; challenges in integrating and implementing the company's software and software system products, or the slowing or deferral of demand for these products; the company's ability to successfully identify, consummate and integrate strategic acquisitions; changes in generally accepted accounting principles (GAAP); foreign currency fluctuations; and general economic conditions. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The company assumes no obligation to update or revise any such statements, whether as a result of new information or otherwise.

A Webcast of the company's regular conference call to review financial results with the financial community is available through McKesson's website, www.mckesson.com, live at 5 PM ET today and on replay afterwards. Shareholders are encouraged to review SEC filings and more information about McKesson, which are located on the company's website.

About McKesson

McKesson Corporation (NYSE:MCK) is a Fortune 15 healthcare services and information technology company dedicated to helping its customers deliver high-quality healthcare by reducing costs, streamlining processes and improving the quality and safety of patient care. Over the course of its 172-year history, McKesson has grown by providing pharmaceutical and medical-surgical supply management across the spectrum of care; healthcare information technology for hospitals, physicians, homecare and payors; hospital and retail pharmacy automation; and services for manufacturers and payors designed to improve outcomes for patients. For more information, visit us at www.mckesson.com.

                                                            Schedule I
                                                            ----------

                         McKESSON CORPORATION
           CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                             (unaudited)
                (in millions except per share amounts)


                             Quarter Ended         Six Months Ended
                             September 30,          September 30,
                         ---------------------- ----------------------
                           FY06     FY05   Chg.   FY06     FY05   Chg.
                         -------- -------- ---- -------- -------- ----

Revenues                 $21,605  $19,922    8% $42,663  $39,097    9%

Cost of sales             20,711   19,191    8   40,844   37,517    9
                         -------- --------      -------- --------

  Gross profit               894      731   22    1,819    1,580   15

Operating expenses           665      603   10    1,277    1,192    7
Securities Litigation
 charge                        -        -    -       52        -    -
                         -------- --------      -------- --------
    Total operating
     expenses                665      603   10    1,329    1,192   11
                         -------- --------      -------- --------

  Operating income           229      128   79      490      388   26

Interest expense             (22)     (30) (27)     (47)     (60) (22)

Other income, net             35       15  133       63       30  110
                         -------- --------      -------- --------

  Income from continuing
   operations before
   income taxes              242      113  114      506      358   41

Income taxes                 (88)     (27) 226     (182)    (109)  67
                         --------  -------      -------- --------

  Income from continuing
   operations                154       86   79      324      249   30

Discontinued operation,
 net                          13        -    -       14        1    -
                         -------- --------      -------- --------

  Net income             $   167  $    86   94  $   338  $   250   35
                         ======== ========      ======== ========

Earnings per common
 share (1)
  Diluted (2) (3)
    Continuing
     operations          $  0.49  $  0.29   69% $  1.03  $  0.84   23%
    Discontinued
     operation              0.04        -    -     0.05        -    -
                         -------- --------      -------- --------
      Total              $  0.53  $  0.29   83  $  1.08  $  0.84   29
                         ========  =======      ======== ========
  Basic
    Continuing
     operations          $  0.50  $  0.29   72% $  1.06  $  0.85   25%
    Discontinued
     operation              0.04        -    -     0.05        -    -
                         -------- --------      -------- --------
      Total              $  0.54  $  0.29   86  $  1.11  $  0.85   31
                         ======== ========      ======== ========

Shares on which earnings
 per common share were
 based
    Diluted                  316      300    5%     315      300    5%
    Basic                    308      293    5%     305      292    4%

(1) Certain computations may reflect rounding adjustments.

(2) For the quarter ended September 30, 2004 and six months ended
    September 30, 2005 and 2004, interest expense, net of related
    income taxes, of $1 million, $1 million and $3 million has been
    added to net income for purposes of calculating diluted earnings
    per share. This adjustment reflects the impact of the Company's
    potentially dilutive obligations.

(3) Diluted earnings per share, excluding the Securities Litigation
    charge, is as follows:

                                                  Six Months Ended
                                                     September 30,
                                                ----------------------
                                                  FY06     FY05   Chg.
                                                -------- -------- ----
    Net income - as reported                    $   338  $   250   35%
                                                -------- --------

    Exclude: Securities Litigation charge            52        -    -
             Estimated income tax benefit           (17)       -    -
                                                -------- --------
                                                     35        -    -
                                                -------- --------

    Net income, excluding Securities Litigation
     charge                                     $   373  $   250   49%
                                                ======== ========

    Diluted earnings per common share,
     excluding Securities Litigation charge     $  1.19  $  0.84   42%



                                                           Schedule II
                                                           -----------

                         McKESSON CORPORATION
     CONDENSED CONSOLIDATED INCOME INFORMATION BY BUSINESS SEGMENT
                             (unaudited)
                            (in millions)


                         Quarter Ended           Six Months Ended
                         September 30,             September 30,
                   ------------------------- -------------------------
                     FY06     FY05    Chg.     FY06     FY05    Chg.
                   -------- -------- ------- -------- -------- -------
REVENUES
Pharmaceutical
 Solutions
  U.S. Healthcare
   direct
   distribution &
   services        $12,762  $11,625    10%   $25,113  $22,625    11%
  U.S. Healthcare
   sales to
   customers'
   warehouses        6,247    6,021     4     12,373   11,937     4
                   -------- --------         -------- --------
    Subtotal        19,009   17,646     8     37,486   34,562     8
  Canada
   distribution &
   services          1,467    1,258    17      2,954    2,510    18
                   -------- --------         -------- --------
    Total
     Pharmaceutical
     Solutions      20,476   18,904     8     40,440   37,072     9
                   -------- --------         -------- --------

Medical-Surgical
 Solutions             769      714     8      1,513    1,421     6
                   -------- --------         -------- --------

Provider
 Technologies
  Software &
   software systems     66       50    32        128      101    27
  Services             259      229    13        513      451    14
  Hardware              35       25    40         69       52    33
                   -------- --------         -------- --------
    Total Provider
     Technologies      360      304    18        710      604    18
                   -------- --------         -------- --------
    Revenues       $21,605  $19,922     8    $42,663  $39,097     9
                   ======== ========         ======== ========

GROSS PROFIT
Pharmaceutical
 Solutions         $   566  $   428    32    $ 1,160  $   985    18
Medical-Surgical
 Solutions             167      162     3        336      321     5
Provider
 Technologies          161      141    14        323      274    18
                   -------- --------         -------- --------
    Gross profit   $   894  $   731    22    $ 1,819  $ 1,580    15
                   ======== ========         ======== ========

OPERATING EXPENSES
Pharmaceutical
 Solutions         $   322  $   284    13    $   622  $   557    12
Medical-Surgical
 Solutions             145      145     -        286      276     4
Provider
 Technologies          140      125    12        273      245    11
Corporate               58       49    18         96      114   (16)
                   -------- --------         -------- --------
    Subtotal           665      603    10      1,277    1,192     7
Securities
 Litigation charge       -        -     -         52        -     -
                   -------- --------         -------- --------
    Operating
     expenses      $   665  $   603    10    $ 1,329  $ 1,192    11
                   ======== ========         ======== ========

OTHER INCOME, NET
Pharmaceutical
 Solutions         $     8  $     5    60    $    16  $    11    45
Medical-Surgical
 Solutions               1        1     -          2        2     -
Provider
 Technologies            5        3    67          7        4    75
Corporate               21        6   250         38       13   192
                   -------- --------         -------- --------
    Other income,
     net           $    35  $    15   133    $    63  $    30   110
                   ======== ========         ======== ========

OPERATING PROFIT
Pharmaceutical
 Solutions         $   252  $   149    69    $   554  $   439    26
Medical-Surgical
 Solutions              23       18    28         52       47    11
Provider
 Technologies           26       19    37         57       33    73
                   -------- --------         -------- --------
    Operating
     profit            301      186    62        663      519    28
Corporate              (37)     (43)  (14)       (58)    (101)  (43)
Securities
 Litigation charge       -        -     -        (52)       -     -
                   -------- --------         -------- --------
    Income from
     continuing
     operations
     before
     interest
     expense and
     income taxes  $   264  $   143    85    $   553  $   418    32
                   ======== ========         ======== ========
STATISTICS
Operating profit as
 a % of revenues
  Pharmaceutical
   Solutions          1.23%    0.79%   44bp     1.37%    1.18%   19bp
  Medical-Surgical
   Solutions          2.99%    2.52%   47       3.44%    3.31%   13
  Provider
   Technologies       7.22%    6.25%   97       8.03%    5.46%  257

Return on
 Stockholders'
 Equity (1)          (1.3%)    11.3%    -

(1) Ratio is computed as the sum of net income (loss) for the last
    four quarters, divided by the average of stockholders' equity for
    the last five quarters. Ratio includes the $810 million and $35
    million after-tax Securities Litigation charges recorded in the
    third quarter of 2005 and the first quarter of 2006.



                                                          Schedule III
                                                          ------------

                         McKESSON CORPORATION
                CONDENSED CONSOLIDATED BALANCE SHEETS
                             (unaudited)
                            (in millions)


                                           September 30,   March 31,
                                               2005          2005
                                           ------------- -------------

ASSETS
  Current Assets
    Cash and cash equivalents                  $  2,996      $  1,800
    Receivables, net                              5,855         5,721
    Inventories                                   7,588         7,495
    Prepaid expenses and other                      246           346
                                           ------------- -------------
      Total                                      16,685        15,362
  Property, Plant and Equipment, net                649           616
  Capitalized Software Held for Sale                130           130
  Notes Receivable                                  119           163
  Goodwill and Other Intangibles                  1,826         1,529
  Other Assets                                    1,047           975
                                           ------------- -------------
      Total Assets                             $ 20,456      $ 18,775
                                           ============= =============

LIABILITIES AND STOCKHOLDERS' EQUITY
  Current Liabilities
    Drafts and accounts payable                $ 10,055      $  8,733
    Deferred revenue                                539           593
    Current portion of long-term debt                 6             9
    Securities Litigation                         1,183         1,200
    Other                                         1,227         1,257
                                           ------------- -------------
      Total                                      13,010        11,792
  Postretirement Obligations and Other
   Noncurrent Liabilities                           605           506
  Long-Term Debt                                    988         1,202
  Stockholders' Equity                            5,853         5,275
                                           ------------- -------------
      Total Liabilities and Stockholders'
       Equity                                  $ 20,456      $ 18,775
                                           ============= =============



                                                           Schedule IV
                                                           -----------

                         McKESSON CORPORATION
           CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                             (unaudited)
                            (in millions)


                                                    Six Months Ended
                                                      September 30,
                                                   -------------------
                                                     FY06      FY05
                                                   --------- ---------
OPERATING ACTIVITIES
  Income from continuing operations                 $   324   $   249
  Adjustments to reconcile to net cash provided by
   (used in) operating activities:
    Depreciation and amortization                       127       122
    Securities Litigation charge, net of tax             35         -
    Securities Litigation settlement payments           (69)        -
    Deferred taxes                                      111       123
    Other non-cash items                                  2         7
                                                   --------- ---------
      Total                                             530       501
                                                   --------- ---------
  Effects of Changes In:
    Receivables                                          62      (192)
    Inventories                                         253    (1,172)
    Drafts and accounts payable                       1,108     1,317
    Deferred revenue                                    101       (75)
    Taxes                                                29       (54)
  Proceeds from sale of notes receivable                 28        39
  Other                                                (102)        1
                                                   --------- ---------
      Total                                           1,479      (136)
                                                   --------- ---------
      Net cash provided by operating activities       2,009       365
                                                   --------- ---------

INVESTING ACTIVITIES
  Property acquisitions                                 (83)      (53)
  Capitalized software expenditures                     (66)      (66)
  Acquisitions of businesses, less cash and cash
   equivalents acquired                                (575)      (48)
  Proceeds from sale of business                         63        12
  Other                                                   3        19
                                                   --------- ---------
      Net cash used in investing activities            (658)     (136)
                                                   --------- ---------

FINANCING ACTIVITIES
  Repayment of debt                                     (20)      (14)
  Capital stock transactions:
    Issuances                                           282        89
    Share repurchases                                  (290)        -
    ESOP notes and guarantees                             9        13
    Dividends paid                                      (36)      (35)
  Other                                                (100)        6
                                                   --------- ---------
      Net cash provided by (used in) financing
       activities                                      (155)       59
                                                   --------- ---------

Net increase in cash and cash equivalents             1,196       288
Cash and cash equivalents at beginning of period      1,800       708
                                                   --------- ---------
Cash and cash equivalents at end of period          $ 2,996   $   996
                                                   ========= =========

 

PR Contact

McKesson Corporate Media Relations
415-983-8988
CorporateMediaRelations@McKesson.com

  • facebook
  • twitter
  • linkedin
  • Instagram
  • youtube
  • rss
  • About McKesson
  • Who We Are
  • Our Values
  • Locations
  • McKesson Vision Centers
  • Corporate Social Responsibility
  • Newsroom
  • Event Calendar
  • Connect With McKesson
  • Blog
  • Careers
  • Find A Job
  • Campus Recruiting
  • Popular Products
  • Medical Supplies
  • Pharmaceutical Distribution
  • Solutions for Drug Manufacturers
  • iKnowMed
  • Health Mart
  • OneStop Generics Purchasing
  • Plasma and Biologics Distribution
  • Pharmacy Management Software & Services
  • Resources
  • Explainer: Medication Dispensing
  • Explainer: Unit Dose Packaging
  • Customer Ordering
  • Pharmaceuticals: Branded & Generic
  • Specialty and Oncology Drugs
  • Plasma Products
  • Medical Supplies & Equipment
  • Homecare Products for Consumers
  • Investors
  • Financial News
  • Events
  • Financial Information
  • Stock Information
  • Investor Alerts
  • Corporate Governance
  • Our Businesses
  • U.S. Pharmaceutical
  • Medical-Surgical
  • Specialty Health
  • Pharmacy Systems
  • RelayHealth
  • High Volume Solutions
  • McKesson International
  • McKesson Canada
  • McKesson Europe
  • McKesson Ventures
Business Care Connectivity
  • Contact Us
  • Privacy Notice
  • Disclaimer
  • Patents
  • Site Map

© 2018 McKesson Corporation

top

  • Careers
  • Investors
  • Contact Us
  • Customer Logins

close